147 related articles for article (PubMed ID: 34423769)
1. An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis.
Zhao Q; Chen X; Jiang J; Li J; Zhong W; Han H; Li Z; Leung SO; Zhang F; Hu P
Int J Clin Pharmacol Ther; 2021 Nov; 59(11):691-704. PubMed ID: 34423769
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.
Zhao Q; Chen X; Li J; Jiang J; Li M; Zhong W; Li Z; Leung SO; Zhang F; Hu P
Clin Drug Investig; 2016 Nov; 36(11):889-902. PubMed ID: 27424629
[TBL] [Abstract][Full Text] [Related]
3. SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study.
Li J; Li M; Wu D; Zhou J; Leung SO; Zhang F
Rheumatology (Oxford); 2022 May; 61(5):1841-1848. PubMed ID: 34508557
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.
Li S; Zhang D; Sun J; Li Z; Deng L; Zou B; Zhan J; Jiang W
MAbs; 2012; 4(2):256-66. PubMed ID: 22453099
[TBL] [Abstract][Full Text] [Related]
5. Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.
Leung SO; Gao K; Wang GY; Cheung BK; Lee KY; Zhao Q; Cheung WT; Wang JZ
MAbs; 2015; 7(1):66-76. PubMed ID: 25427174
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
8. SM03, an Anti-CD22 Antibody, Converts
Wong KL; Li Z; Ma F; Wang D; Song N; Chong CH; Luk KK; Leung SO
J Immunol; 2022 Jun; 208(12):2726-2737. PubMed ID: 35688465
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
Witcher J; Fleischmann R; Chindalore VL; Hansen RJ; Hu L; Radtke D; Voelker J; Gomez E; McColm J
Br J Clin Pharmacol; 2016 May; 81(5):908-17. PubMed ID: 26648084
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.
Choy EH; Bendit M; McAleer D; Liu F; Feeney M; Brett S; Zamuner S; Campanile A; Toso J
Arthritis Res Ther; 2013 Sep; 15(5):R132. PubMed ID: 24286335
[TBL] [Abstract][Full Text] [Related]
11. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus.
Zhao Q; Chen X; Hou Y; Jiang J; Zhong W; Yao X; Wang W; Li L; Fang J; Zhang F; Hu P
J Clin Pharmacol; 2016 Aug; 56(8):948-59. PubMed ID: 26634642
[TBL] [Abstract][Full Text] [Related]
14. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
Tsuru T; Tanaka Y; Kishimoto M; Saito K; Yoshizawa S; Takasaki Y; Miyamura T; Niiro H; Morimoto S; Yamamoto J; Lledo-Garcia R; Shao J; Tatematsu S; Togo O; Koike T
Mod Rheumatol; 2016; 26(1):87-93. PubMed ID: 26382733
[TBL] [Abstract][Full Text] [Related]
16. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.
Martin DA; Churchill M; Flores-Suarez L; Cardiel MH; Wallace D; Martin R; Phillips K; Kaine JL; Dong H; Salinger D; Stevens E; Russell CB; Chung JB
Arthritis Res Ther; 2013 Oct; 15(5):R164. PubMed ID: 24286136
[TBL] [Abstract][Full Text] [Related]
17. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
[TBL] [Abstract][Full Text] [Related]
18. Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03.
Zhao Q; Wong PF; Lee SS; Leung SO; Cheung WT; Wang JZ
PLoS One; 2014; 9(5):e96697. PubMed ID: 24816427
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics.
Kurrasch R; Brown JC; Chu M; Craigen J; Overend P; Patel B; Wolfe S; Chang DJ
J Rheumatol; 2013 Jul; 40(7):1089-96. PubMed ID: 23729801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
